Founded in the early 1960s by Pierre Fabre, a pharmacist at Castres (Tarn, France), our laboratories have been focusing for more than 50 years on three complementary activities: prescription drugs, health and dermo-cosmetics.

Pierre Fabre, it's quite a story

On October 31stÉditions Privat published the book "Histoire des Laboratoires Pierre Fabre" (History of Pierre Fabre Laboratories), written by Hervé Penan, Professor of Management at Université Toulouse-Capitole.

Subtitled "Innovating, from health to beauty", this academic work takes the reader on a journey to discover events spanning six decades which led to the creation of the Pierre Fabre Group. The book is organized chronologically, and traces the history of the Group over the course of five chapters, from the 1950s up to 2010. Each chapter is accompanied by a collection of images.

This book is meant to be read and shared to preserve the memory of our history, and to introduce and explain the specific nature and values of our Group.

The English version has been available since July 2015.

pages_livre_histoire_pf.jpg

 

KEY EVENTS

  • 1951: purchase of the Pierre Fabre pharmacy, Jean Jaurès square, Castres (Tarn)
  • 1959: launch of Cyclo 3, a venotonic derived from butcher’s broom (Ruscus aculeatus)
  • 1962: constituent general assembly of Pierre Fabre laboratories
  • 1965: start of the dermo-cosmetic activity
  • 1968: inauguration of the first research center
  • 1970: opening of the first subsidiary in Spain
  • 1974: purchase of the hydrotherapy station at Avène-les-Bains (Hérault)
  • 1989: launch of the anti-cancer drug Navelbine
  • 1990: launch of the Avène Thermal Spring Water brand
  • 1999: creation of the Pierre Fabre Foundation, recognized as being of public utility
  • 2005: opening up of business capital to employees
  • 2010: opening of the R&D center on the Oncopole campus at Toulouse

1950/1960

  • 1951: purchase of the Pierre Fabre pharmacy, Jean Jaurès square, Castres (Tarn)
  • 1959: launch of Cyclo 3, a venotonic derived from butcher’s broom (Ruscus aculeatus)

1960/1970

  • 1961: the success of Cyclo 3 leads Pierre Fabre to create his laboratories
  • 1962: Pierre Fabre Laboratories constituent general assembly
  • 1963: acquisition of Laboratoires Inava (oral and dental hygiene and care products)
  • 1965: acquisition of the Klorane brand: start of the dermo-cosmetic activity
  • 1968: creation of the first Pierre Fabre Research Center at Péraudel (Castres)
  • 1969: acquisition of the Ducray brand
  • 1969: opening of the first production unit at Soual (new Castres)
The company already relied on the same strengths as it does today: complementary activities, sustained R&D investments, product safety and efficacy due to mastering their life cycle.

1970/1980

  • 1970: opening of the first international subsidiaries in Spain
  • 1973: opening of affiliates in Italy and Switzerland
  • 1974: purchase of the hydrotherapy station at Avène-les-Bains (Hérault)
  • 1974: first distribution center at Muret (near Toulouse)
  • 1976: creation of a plant extraction and fine chemical unit at Gaillac (Tarn) for the production of pharmaceutical and dermo-cosmetic active substances
  • 1978: launch of the Galénic brand
  • 1979: acquisition of the René Furterer brand
  • 1979: creation of a joint venture in Japan with Shiseido

1980/1990

  • 1980: opening of a subsidiary in Greece
  • 1982: launch of Permixon® (treatment of benign prostatic hypertrophy)
  • 1982: launch of the A-Derma brand
  • 1985: first framework contract with the CNRS
  • 1986: creation of Pierre Fabre Japan
  • 1987: opening of a dermo-cosmetic research center at Vigoulet (Toulouse) and of the skin culture center (Toulouse)
  • 1988: opening of a subsidiary in Portugal
  • 1988: launch of the Plants and Medicines brand (later to become Naturactive)
  • 1989: acquisition of the Robapharm laboratories (Switzerland)
  • 1989: creation of Pierre Fabre Oncology and launch of Navelbine®

1990/2000

  • 1990: launch of the Avène Thermal Spring Water brand
  • 1990: opening of the Immunology Research Center in Saint-Julien-en-Genevois
  • 1991: opening of the factory at Pau (for sterile injectable drugs)
  • 1992: opening of the factory at Gien (prescription products)
  • 1992: launch of Nicopatch® (for smoking cessation)
  • 1994: creation of the Klorane Institute
  • 1995: Navelbine® approved by the US health authorities
  • 1997: launch of Ixel® (depressive disorders)
  • 1999: the Pierre Fabre Foundation is recognized as being of public utility

2000/2012

  • 2001: creation of Orfagen (orphan diseases)
  • 2001: creation of the Oceanology Observatory at Banyuls-sur-Mer (partnership with Laboratoires Arago, CNRS)
  • 2001: opening of the Botanical Conservatory in Soual
  • 2002: purchase of Genesis Laboratories (Glytone® brand) in the US
  • 2005: opening up of company capital to employees
  • 2006: purchase of Darrow laboratories and brand in Brazil
  • 2007: launch of Xelevia® (diabetes) as co-marketing with Merck Sharp & Dohme-Chibret
  • 2008: agreements with Forest for the development and marketing in the North America of levomilnacipran, a molecule derived from Pierre Fabre research for the treatment of depression
  • 2008: DEFI technology, a patented packaging system that guarantees complete sterility for the product throughout use
  • 2009: Marketing Authorization for Javlor® in the treatment of the bladder cancer
  • 2009: scientific partnership with the University of Bordeaux and Bordeaux University Hospital Center for the development of a molecule for the treatment of infantile hemangioma
  • 2010: agreement with Abbott Laboratories for the development and marketing of a monoclonal antibody
  • 2010: opening of an R&D Center at the Toulouse Oncopole campus

2010/2020

  • 2012: construction of an Antibody Biotechnology Unit (clinical batch production) at the Research Center at Saint-Julien-en-Genevois
  • 2012: extension of the Soual factory and opening of a sterile cosmetics production unit
  • 2012 : first company with over 10,000 employees to be granted AFAQ 26000 at the “Confirmed” level for its contribution to sustainable development
  • 2013 : the Pierre Fabre Foundation becomes the majority shareholder with 86% of the shares